Share:
Share this content in WeChat
X
Clinlcal Guidelines & Expert Consensus
Chinese expert consensus on MRI evaluation of endocrine system immune-related adverse events induced by immune checkpoint inhibitors in malignant tumors
Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association
MRI Group of Chinese Society of Radiology Chinese Medical Association
Neurology Group of Chinese Society of Radiology Chinese Medical Association
Editorial Board of Chinese Journal of Magnetic Resonance Imaging

Cite this article as: Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association, MRI Group of Chinese Society of Radiology Chinese Medical Association, Neurology Group of Chinese Society of Radiology Chinese Medical Association, et al. Chinese expert consensus on MRI evaluation of endocrine system immune-related adverse events induced by immune checkpoint inhibitors in malignant tumors[J]. Chin J Magn Reson Imaging, 2024, 15(12): 19-27. DOI:10.12015/issn.1674-8034.2024.12.003.


[Abstract] Immune checkpoint inhibitors (ICIs) demonstrate potent anti-tumor effects by reactivating effector T cells to eliminate cancer cells. However, this modulation of the immune response can also lead to activation of immune cells, triggering autoimmune damage, known as immune-related adverse events (irAEs). Among these adverse reactions, endocrine system disorders are particularly common, primarily affecting endocrine glands such as the thyroid, pituitary, and adrenal glands, leading to endocrine dysfunction. MRI plays a crucial role in the early diagnosis and assessment of endocrine system irAEs. However, there is currently no standardized consensus in China regarding MRI examination and diagnosis of endocrine system irAEs caused by ICIs. For this purpose, the Molecular Imaging Group, Magnetic Resonance Group, and Neurology Group of the Radiology Branch of the Chinese Medical Association, together with the Editorial Board of Chinese Journal of Magnetic Resonance Imaging, jointly established an expert committee. Drawing extensively from the literature, combined with expert experience and internal discussions, the committee ultimately developed this consensus. The aim of this consensus is to provide guidance and support to radiologists and clinicians in diagnosing endocrine system irAEs using MRI.
[Keywords] magnetic resonance imaging;immune checkpoint inhibitors;endocrine system immune-related adverse events;clinical application;expert consensus

Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association   MRI Group of Chinese Society of Radiology Chinese Medical Association   Neurology Group of Chinese Society of Radiology Chinese Medical Association   Editorial Board of Chinese Journal of Magnetic Resonance Imaging  

Corresponding author: SUN H Z (Department of Radiology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110004, China), E-mail: sunhongzan@126.com JU S H (Department of Radiology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China), E-mail: jsh@seu.edu.cn

Conflicts of interest   None.

Received  2024-10-01
Accepted  2024-12-10
DOI: 10.12015/issn.1674-8034.2024.12.003
Cite this article as: Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association, MRI Group of Chinese Society of Radiology Chinese Medical Association, Neurology Group of Chinese Society of Radiology Chinese Medical Association, et al. Chinese expert consensus on MRI evaluation of endocrine system immune-related adverse events induced by immune checkpoint inhibitors in malignant tumors[J]. Chin J Magn Reson Imaging, 2024, 15(12): 19-27. DOI:10.12015/issn.1674-8034.2024.12.003.

[1]
BAGCHI S, YUAN R, ENGLEMAN E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249. DOI: 10.1146/annurev-pathol-042020-042741.
[2]
LEE P Y, OEN K Q X, LIM G R S, et al. Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study[J/OL]. Cancers, 2021, 13(6): 1308 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/33804050/. DOI: 10.3390/cancers13061308.
[3]
TAN M H, IYENGAR R, MIZOKAMI-STOUT K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports[J/OL]. Clin Diabetes Endocrinol, 2019, 5: 1 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/30693099/. DOI: 10.1186/s40842-018-0073-4.
[4]
WRIGHT J J, POWERS A C, JOHNSON D B. Endocrine toxicities of immune checkpoint inhibitors[J]. Nat Rev Endocrinol, 2021, 17(7): 389-399. DOI: 10.1038/s41574-021-00484-3.
[5]
ATKINSON M, LANSDOWN A J. Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy[J/OL]. Best Pract Res Clin Endocrinol Metab, 2022, 36(3): 101635 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/35382989/. DOI: 10.1016/j.beem.2022.101635.
[6]
BERZ A M, BOUGHDAD S, VIETTI-VIOLI N, et al. Imaging assessment of toxicity related to immune checkpoint inhibitors[J/OL]. Front Immunol, 2023, 14: 1133207 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/36911692/. DOI: 10.3389/fimmu.2023.1133207.
[7]
ZHAO P F, ZHAO T, YU L H, et al. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis[J/OL]. Front Oncol, 2024, 14: 1381250 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/38756658/. DOI: 10.3389/fonc.2024.1381250.
[8]
BARROSO-SOUSA R, BARRY W T, GARRIDO-CASTRO A C, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(2): 173-182. DOI: 10.1001/jamaoncol.2017.3064.
[9]
FAJE A T, SULLIVAN R, LAWRENCE D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma[J]. J Clin Endocrinol Metab, 2014, 99(11): 4078-4085. DOI: 10.1210/jc.2014-2306.
[10]
WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018.3923.
[11]
FERRARI S M, FALLAHI P, ELIA G, et al. Autoimmune endocrine dysfunctions associated with cancer immunotherapies[J/OL]. Int J Mol Sci, 2019, 20(10): 2560 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/31137683/. DOI: 10.3390/ijms20102560.
[12]
GU Y C, XIE C, CAO B S. Immune checkpoint inhibitors induced pituitary immune-related adverse events: diagnosis and management[J]. Chin J Oncol, 2022, 44(12): 1344-1351. DOI: 10.3760/cma.j.cn112152-20211223-00967.
[13]
TANG Q R, HAN Y R, SONG M, et al. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database[J/OL]. Medicine, 2024, 103(13): e37587 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/38552079/. DOI: 10.1097/MD.0000000000037587.
[14]
HODI F S, CHIARION-SILENI V, GONZALEZ R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(11): 1480-1492. DOI: 10.1016/S1470-2045(18)30700-9.
[15]
YOO W S, KU E J, LEE E K, et al. Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: a meta-analysis and comprehensive review[J]. Endocrinol Metab, 2023, 38(6): 750-759. DOI: 10.3803/EnM.2023.1785.
[16]
BAI X F, LIN X H, ZHENG K N, et al. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase[J]. Endocrine, 2020, 69(3): 670-681. DOI: 10.1007/s12020-020-02355-9.
[17]
CASTINETTI F, ALBAREL F, ARCHAMBEAUD F, et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy[J/OL]. Endocr Relat Cancer, 2019, 26(2): G1-G18 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/30400055/. DOI: 10.1530/ERC-18-0320.
[18]
CHANG L S, BARROSO-SOUSA R, TOLANEY S M, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J]. Endocr Rev, 2019, 40(1): 17-65. DOI: 10.1210/er.2018-00006.
[19]
HAANEN J, OBEID M, SPAIN L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(12): 1217-1238. DOI: 10.1016/j.annonc.2022.10.001.
[20]
BRAHMER J R, LACCHETTI C, THOMPSON J A. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary[J]. J Oncol Pract, 2018, 14(4): 247-249. DOI: 10.1200/JOP.18.00005.
[21]
PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J/OL]. J Immunother Cancer, 2017, 5(1): 95 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/29162153/. DOI: 10.1186/s40425-017-0300-z.
[22]
BORNSTEIN S R, ALLOLIO B, ARLT W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2016, 101(2): 364-389. DOI: 10.1210/jc.2015-1710.
[23]
ZHAO C, TELLA S H, DEL RIVERO J, et al. Anti-PD-L1 treatment induced central diabetes insipidus[J]. J Clin Endocrinol Metab, 2018, 103(2): 365-369. DOI: 10.1210/jc.2017-01905.
[24]
RYDER M, CALLAHAN M, POSTOW M A, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution[J]. Endocr Relat Cancer, 2014, 21(2): 371-381. DOI: 10.1530/ERC-13-0499.
[25]
BASCHIERI L, ANTONELLI A, NARDI S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy[J]. Thyroid, 1997, 7(4): 579-585. DOI: 10.1089/thy.1997.7.579.
[26]
JUSZCZAK A, GUPTA A, KARAVITAKI N, et al. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review[J]. Eur J Endocrinol, 2012, 167(1): 1-5. DOI: 10.1530/EJE-12-0167.
[27]
FAJE A, REYNOLDS K, ZUBIRI L, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis[J]. Eur J Endocrinol, 2019, 181(3): 211-219. DOI: 10.1530/EJE-19-0238.
[28]
XU C Y, RICCIUTI A, CATUREGLI P, et al. Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab[J]. Pituitary, 2015, 18(4): 441-447. DOI: 10.1007/s11102-014-0592-7.
[29]
NARAN J, CAN A S. Lymphocytic Hypophysitis[M]. StatPearls, Treasure Island (FL): StatPearls, 2023.
[30]
KUROKAWA R, OTA Y, GONOI W, et al. MRI findings of immune checkpoint inhibitor-induced hypophysitis: possible association with fibrosis[J]. AJNR Am J Neuroradiol, 2020, 41(9): 1683-1689. DOI: 10.3174/ajnr.A6692.
[31]
CATUREGLI P, DALMAZI G D, LOMBARDI M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series[J]. Am J Pathol, 2016, 186(12): 3225-3235. DOI: 10.1016/j.ajpath.2016.08.020.
[32]
MAHZARI M, LIU D, ARNAOUT A, et al. Immune checkpoint inhibitor therapy associated hypophysitis[J]. Clin Med Insights Endocrinol Diabetes, 2015, 8: 21-28. DOI: 10.4137/CMED.S22469.
[33]
GO J L, RAJAMOHAN A G. Imaging of the sella and parasellar region[J]. Radiol Clin North Am, 2017, 55(1): 83-101. DOI: 10.1016/j.rcl.2016.09.002.
[34]
GADELHA M R, BARBOSA M A, LAMBACK E B, et al. Pituitary MRI standard and advanced sequences: role in the diagnosis and characterization of pituitary adenomas[J]. J Clin Endocrinol Metab, 2022, 107(5): 1431-1440. DOI: 10.1210/clinem/dgab901.
[35]
EXPERT PANEL ON NEUROLOGIC IMAGING, BURNS J, POLICENI B, et al. ACR appropriateness criteria® neuroendocrine imaging[J/OL]. J Am Coll Radiol, 2019, 16(5S): S161-S173 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/31054742/. DOI: 10.1016/j.jacr.2019.02.017.
[36]
CARANCI F, LEONE G, PONSIGLIONE A, et al. Imaging findings in hypophysitis: a review[J]. Radiol Med, 2020, 125(3): 319-328. DOI: 10.1007/s11547-019-01120-x.
[37]
JOSHI M N, WHITELAW B C, CARROLL P V. MECHANISMS IN ENDOCRINOLOGY: Hypophysitis: diagnosis and treatment[J/OL]. Eur J Endocrinol, 2018, 179(3): R151-R163 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/29880706/. DOI: 10.1530/EJE-17-0009.
[38]
GUTENBERG A, LARSEN J, LUPI I, et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively[J]. AJNR Am J Neuroradiol, 2009, 30(9): 1766-1772. DOI: 10.3174/ajnr.A1714.
[39]
NAKATA Y, SATO N, MASUMOTO T, et al. Parasellar T2 dark sign on MR imaging in patients with lymphocytic hypophysitis[J]. AJNR Am J Neuroradiol, 2010, 31(10): 1944-1950. DOI: 10.3174/ajnr.A2201.
[40]
CAI Q Q, WU W, LI X Y, et al. Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis[J]. J Cancer Res Clin Oncol, 2023, 149(15): 14113-14123. DOI: 10.1007/s00432-023-05093-3.
[41]
LU D, YAO J, YUAN G, et al. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS[J]. J Endocrinol Invest, 2022, 45(11): 2131-2137. DOI: 10.1007/s40618-022-01845-z.
[42]
CARDONA Z, SOSMAN J A, CHANDRA S, et al. Endocrine side effects of immune checkpoint inhibitors[J/OL]. Front Endocrinol, 2023, 14: 1157805 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/37251665/. DOI: 10.3389/fendo.2023.1157805.
[43]
HATTERSLEY R, NANA M, LANSDOWN A J. Endocrine complications of immunotherapies: a review[J/OL]. Clin Med, 2021, 21(2): e212-e222 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/33762389/. DOI: 10.7861/clinmed.2020-0827.
[44]
Immune-endocrinology Group of Endocrinology Branch of Chinese Medical Association. Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events (2020)[J]. Chin J Endocrinol Metab, 2021, 37(1): 1-16. DOI: 10.3760/cma.j.cn311282-20200627-00475.

PREV Consensus of Chinese experts on cardiovascular MRI in evaluating immune-related adverse cardiac events associated with immune checkpoint inhibitors for malignant tumors
NEXT Chinese expert consensus on the evaluation of abdominal immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn